A DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF-00915275 AFTER ORAL ADMINISTRATION TO SUBJECTS WITH TYPE 2 DIABETES MELLITUS FOR 4-WEEKS.
- Conditions
- Type 2 diabetes mellitusMedDRA version: 9.1Level: LLTClassification code 10012601Term: Diabetes mellitus
- Registration Number
- EUCTR2006-006768-53-BE
- Lead Sponsor
- Pfizer Global Research & Development
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Subjects with type 2 diabetes mellitus diagnosed in accordance with the ADA
guidelines.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Recent (within the past 12 months) evidence or history of unstable concomitant disease.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method